TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24178765
Drug: Alcohol in
Normalized name: WATER/BENZYL ALCOHOL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol in combination with energy drink at a dose of 250 ml
Study: 21175704
Drug: Generic omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic omeprazole 20 mg once daily
Study: 18511540
Drug: Topical travoprost
Normalized name: Travoprost
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical travoprost 0.004% once daily for 6 months
Study: 16970646
Drug: Mid-morning nutritional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mid-morning nutritional supplement for 3 weeks
Study: 14556728
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rhGH) 0.05-0.1 mg/kg per day
Study: 24374115
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg over 45 min, second dose)
Study: 24374115
Drug: ECT (electroconvulsive
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECT (electroconvulsive therapy, administered on 3 test days every 48 hours)
Study: 21365332
Drug: Intravesical instillations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillations with 40 ml chondroitin sulfate 0.2% solution
Study: 18959492
Drug: Viral suppression
Normalized name: Buckley's Cough Suppressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viral suppression (continued use of antiretroviral therapy)
Study: 18959492
Drug: Drug conservation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug conservation (interrupt antiretroviral therapy until CD4(+) cell count <250 cells/microL)
Study: 14567368
Drug: Ciclopirox gel
Normalized name: Ciclopirox
DrugBank: Ciclopirox (DB01188)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclopirox gel vehicle applied twice daily for 28 days
Study: 8765259
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (ethinyl estradiol 0.02 mg, desogestrel 0.15 mg) combined with oral danazol 50 mg a day for 21 days of each 28‐day cycle
Study: 1389821
Drug: Separate infusions
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate infusions of propofol and alfentanil
Study: 6698659
Drug: Mepindolol sulfate
Normalized name: mepindolol sulfate
DrugBank: Mepindolol (DB13530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepindolol sulfate 2 X 2.5 mg daily
Study: 28929168
Drug: Ixekizumab (80-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab (80-mg every 4 weeks)
Study: 24617961
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) administered via telemedicine, 10 weekly therapy sessions
Study: 24617961
Drug: Traditional face-to-face
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional face-to-face therapy
Study: 24308672
Drug: TXA-250 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA-250 group (TXA 250 mg)
Study: 24308672
Drug: TXA-500 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA-500 group (TXA 500 mg)
Study: 19000558
Drug: Tablet formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet formulation containing 1,000 mg levetiracetam
Study: 10333196
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg o.d. plus azithromycin 500 mg o.d. and tinidazole 500 mg b.i.d. (PAT)
Study: 7723896
Drug: Diiodohydroxyquinolein (DQ)
Normalized name: diiodohydroxyquinoline
DrugBank: Diiodohydroxyquinoline (DB09115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diiodohydroxyquinolein (DQ) (80 mg/day p.o.)
Study: 7723896
Drug: Zn sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc (DB01593)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zn sulfate plus DQ (100 mg/day Zn sulfate and 80 mg/day DQ p.o.)
Study: 23922179
Drug: Alcohol (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.8 g/kg for men, 0.75 g/kg for women)
Study: 21288119
Drug: Medication management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication management (optional treatment module for ADHD)
Study: 7398002
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (ASA)
Study: 9054843
Drug: Combined ticlopidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined ticlopidine and aspirin (TIC-ASA)
Study: 9448657
Drug: risperidone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: risperidone (2 mg/day)
Study: 7683702
Drug: risperidone (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: risperidone (6 mg/day)
Study: 9448657
Drug: risperidone (6-16
Approvals — FDA: no, EMA: no, PMDA: no
Description: risperidone (6-16 mg/day)
Study: 9448657
Drug: haloperidol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: haloperidol (20 mg/day)
Study: 7683702
Drug: risperidone (2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: risperidone (2, 6, and 16 mg/day)
Study: 3727918
Drug: Tolfenamic acid
Normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolfenamic acid 300 mg/day
Study: 12418118
Drug: Propranolol 120
Normalized name: propranolol 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 120 mg/day
Study: 9024711
Drug: Anastrozole 10
Normalized name: anastrozole 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 10 mg
Study: 27259315
Drug: Levobupivacaine (0.75%)
Normalized name: levobupivacaine 0.75 MG/ML
DrugBank: Levobupivacaine (DB01002)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levobupivacaine (0.75%) with 5 μg mL(‐1) of adrenaline, injected at T 8‐9 interspace, dosage: 1.8 mg kg(‐1), duration: 1.5 min
Study: 23439942
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 0.15% benzydamine hydrochloride
Study: 23439942
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 0.9% normal saline
Study: 17387026
Drug: Aceclofenac 100
Normalized name: aceclofenac 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aceclofenac 100 mg twice daily
Study: 11961179
Drug: meloxicam 7.5
Normalized name: meloxicam 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: meloxicam 7.5 mg bid
Study: 20828790
Drug: naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen 500 mg bid
Study: 9584497
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation of 1000 mg/day
Study: 2137322
Drug: Oral ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ketoconazole therapy
Study: 24461572
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no oral stimulation)
Study: 26829012
Drug: Cabazitaxel with
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabazitaxel with G-CSF
Study: 24251969
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron (1000 mg single administration)
Study: 24251969
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron (200 mg daily for 3 months)
Study: 16191850
Drug: Short contact
Normalized name: BenzePrO Short Contact 9.8 % Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short contact dithranol treatment
Study: 12577228
Drug: Gemcitabine combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine combined with bolus or infusional 5‐fluorouracil, capecitabine, metalloproteinase inhibitors, or FTI tipifarnib
Study: 9578187
Drug: MKS492 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: MKS492 40 mg
Study: 9578187
Drug: MKS492 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: MKS492 20 mg
Study: 2547540
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of Hyalgan (HA, Na-hyaluronate, 20 mg/2 ml)
Study: 17244295
Drug: Cash and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cash and Counseling (treatment group)
Study: 12544376
Drug: Alprazolam 0.25
Normalized name: alprazolam 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 0.25 mg
Study: 21288144
Drug: Alprazolam 0.5
Normalized name: alprazolam 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 0.5 mg
Study: 12544376
Drug: Alprazolam 1
Normalized name: alprazolam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 1 mg
Study: 22762200
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch (21 mg) after overnight smoking abstinence
Study: 14967093
Drug: Unique diagnosis-treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unique diagnosis-treatment pairs analysis
Study: 11285108
Drug: Interactive computer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive computer use with weekly nurse training
Study: 15553106
Drug: cetirizine 10
Normalized name: cetirizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cetirizine 10 mg o.d.
Study: 25296147
Drug: Workplace Exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Workplace Exercise (twice a week for 15 minutes over 10 weeks)
Study: 21138634
Drug: Nucleoside analogue
Normalized name: Nucleoside analogue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleoside analogue therapy (middle stage)
Study: 19910033
Drug: Omalizumab (75-375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab (75-375 mg sc, q2 or q4 wk)
Study: 12694432
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment (n=24)
Study: 12694432
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment (control, n=15)
Study: 3535127
Drug: Cefixime 400
Normalized name: cefixime 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 400 mg once daily
Study: 11605809
Drug: Cefixime 200
Normalized name: cefixime 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 200 mg twice daily
Study: 28958502
Drug: Dacomitinib 45
Normalized name: dacomitinib 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacomitinib 45 mg/day
Study: 23862170
Drug: 14-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day triple therapy
Study: 22654429
Drug: 10-day sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day sequential therapy
Study: 21435093
Drug: 14-day sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day sequential therapy
Study: 21840917
Drug: Robot‐assisted therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot‐assisted therapy
Study: 19672708
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg + Rabeprazole 10 mg
Study: 19672708
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg + Rabeprazole 40 mg
Study: 11821508
Drug: Topical clobetasol
Normalized name: clobetasol Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clobetasol propionate cream (40 g per day)
Study: 11821508
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (0.5 mg/kg/day for moderate disease and 1 mg/kg/day for extensive disease)
Study: 9951426
Drug: Clarithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (500 mg twice a day for 5 days)
Study: 9951426
Drug: Pimozide (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimozide (6 mg oral dose)
Study: 4042390
Drug: Nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20 mg twice daily
Study: 7752176
Drug: Furosemide 60
Normalized name: furosemide 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 60 mg twice daily
Study: 6993446
Drug: Alprazolam (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (1.5 mg/day)
Study: 31532960
Drug: Maribavir (400,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maribavir (400, 800, or 1200 mg twice daily)
Study: 31532960
Drug: Valganciclovir (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valganciclovir (standard dose)
Study: 16053779
Drug: Regular treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular treatment
Study: 19767089
Drug: Methotrexate 3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 3.5 g/m(2) on day 1 plus cytarabine 2 g/m(2) twice a day on days 2-3 (n=39)
Study: 19767089
Drug: Methotrexate 3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 3.5 g/m(2) on day 1 (n=40)
Study: 14722639
Drug: Heparin-coated catheter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated catheter
Study: 11478138
Drug: LH-RH agonist
Normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LH-RH agonist combined with tamoxifen
Study: 11478138
Drug: LH-RH agonist
Normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LH-RH agonist alone
Study: 31420383
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide (NO) at 20 ppm administered into the CPB oxygenator for the duration of CPB
Study: 23340885
Drug: myo-inositol plus
Normalized name: myo-inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: myo-inositol plus 200 µg folic acid twice a day
Study: 23340885
Drug: Placebo (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (200 µg folic acid twice a day)
Study: 21830396
Drug: Supplement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement of 200kcal before endoscopic therapy (n=18)
Study: 21830396
Drug: No energy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No energy supplied (fasting group) before endoscopic therapy (n=18)
Study: 19880429
Drug: MEN11420 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEN11420 2 mg
Study: 19880429
Drug: MEN11420 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEN11420 8 mg
Study: 16309383
Drug: Intra-arterial TNF-alpha
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial TNF-alpha infusion
Study: 15639689
Drug: Tramadol LP
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol LP 200 mg once daily
Study: 11157012
Drug: Combined-modality therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined-modality therapy (neoadjuvant chemotherapy with cyclophosphamide, doxorubicin, and fluorouracil or cyclophosphamide, doxorubicin, vincristine, and prednisone, followed by local therapy and radiotherapy)
Study: 2898536
Drug: Combined-modality therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined-modality therapy
Study: 28454553
Drug: Ambulatory oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambulatory oxygen used during daily activities for a 2-week period at an optimal flow rate determined by titration at screening visit.
Study: 21924624
Drug: Muscle vibration
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscle vibration intervention (12×4 min daily at 100Hz, 0.3mm amplitude) during immobilization
Study: 16696910
Drug: Xuezhikang Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuezhikang Capsules (ZXKC)
Study: 11697808
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day of alendronate, 0.50 microg/day of calcitriol, and 500 mg/day of calcium carbonate
Study: 11697808
Drug: 0.50 microg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50 microg/day of calcitriol and 500 mg/day of calcium carbonate
Study: 9329411
Drug: Hydrophilic gel
Normalized name: PSYLLIUM HYDROPHILIC MUCILLOID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrophilic gel
Study: 7608850
Drug: Amoxicillin/clavulanate potassium
Normalized name: Amoxicillin/Clavulanate Potassium 250 MG-125 MG Oral Tablet
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate potassium during the first 10 post-operative days
Study: 19073976
Drug: Aspirin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (600 mg per day)
Study: 19073976
Drug: Placebo (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (for aspirin group)
Study: 19073976
Drug: Resistant starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant starch (30 g per day)
Study: 15662112
Drug: Oral suspension
Normalized name: Oral Suspension
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral suspension of granisetron (2 mg) and dexamethasone (16 mg for highly emetogenic chemotherapy, 4 mg for moderately emetogenic chemotherapy)
Study: 12662126
Drug: Rituximab 375
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375 mg/m(2) intravenously once weekly for 4 weeks
Study: 3897296
Drug: Aspirin 300
Normalized name: aspirin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 300 mg
Study: 2079176
Drug: Conservative modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative modified MO and DO preparations with glass-ionomer liner
Study: 2079176
Drug: Conventional MO
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional MO and DO preparations with glass-ionomer liner
Study: 2079176
Drug: Conservative modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative modified MO and DO preparations with calcium hydroxide liner
Study: 340333
Drug: Cimetidine, 300
Normalized name: Cimetidine, 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine, 300 mg four times daily
Study: 12121503
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.i.d. with amoxicillin 500 mg t.i.d. and clarithromycin 200 mg t.i.d.
Study: 12121503
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg b.i.d. with amoxicillin 500 mg t.i.d. and clarithromycin 200 mg t.i.d.
Study: 12121503
Drug: Rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 10 mg b.i.d. with amoxicillin 500 mg t.i.d. and clarithromycin 200 mg t.i.d.
Study: 29482528
Drug: Saxagliptin monotherapy
Normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saxagliptin monotherapy
Study: 29482528
Drug: Saxagliptin, metformin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin, metformin, and combination treatment
Study: 29482528
Drug: Saxagliptin and
Normalized name: saxagliptin and dapagliflozin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin and metformin treatments
Study: 22409966
Drug: Nasal antiseptic
Normalized name: 3M Skin and Nasal Antiseptic
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasal antiseptic ointment (oxytetracycline hydrochloride‐polymyxin B sulfate)
Study: 19100932
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of ondansetron (Group O)
Study: 19100932
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of ondansetron plus 20 mg of prochlorperazine (Group OP)
Study: 12771740
Drug: Intracavernous injection
Normalized name: Bivalirudin 250 mg INTRACAVERNOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernous injection of 20 mg prostaglandin E1 within the first 3 months (group 1)
Study: 12771740
Drug: Intracavernous injection
Normalized name: Bivalirudin 250 mg INTRACAVERNOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernous injection of 20 mg prostaglandin E1 at 4 to 12 months (group 2)
Study: 8844449
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg three times a day for 7 days
Study: 1385902
Drug: Methylprednisolone (Depo‐Medrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (Depo‐Medrol 80 mg/ml)
Study: 1385902
Drug: Bupivacaine (Marcaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (Marcaine .5% 1.5 ml)
Study: 6734028
Drug: 400 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 micrograms fenoterol by metered dose inhaler four times a day
Study: 15644588
Drug: Atorvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10 mg/day)
Study: 22900989
Drug: Pitavastatin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin (2 mg/day) for 6 months
Study: 19858319
Drug: Transdermal TPTD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal TPTD patch (20, 30, or 40-microg)
Study: 19858319
Drug: Transdermal TPTD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal TPTD 40-microg patch
Study: 19858319
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (including transdermal TPTD and TPTD injection)
Study: 18662492
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg QD
Study: 2179038
Drug: Cetacaine topical
Normalized name: Cetacaine Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetacaine topical anesthetic spray preparation
Study: 7363933
Drug: Disopyramide capsules
Normalized name: disopyramide Oral Capsule
DrugBank: Disopyramide (DB00280)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disopyramide capsules 150 mg every 6 h for five days
Study: 7363933
Drug: Controlled-release tablets
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release tablets
Study: 7363933
Drug: Disopyramide capsules
Normalized name: disopyramide Oral Capsule
DrugBank: Disopyramide (DB00280)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disopyramide capsules